HER2 levels may aid in treatment selection for metastatic breast cancer
Wednesday, December 3, 2008 - 04:11
in Health & Medicine
Findings published in the 1 December issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent prevents some people from receiving optimal therapy...
Read the whole article on Science Centric
More from Science Centric
Related
- HER2 levels may aid in treatment selection for metastatic breast cancerTue, 2 Dec 2008, 10:49:47 EST
- Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancerThu, 28 May 2009, 17:23:59 EDT
- Triple drug combination is promising option to treat metastatic HER2+ breast cancerFri, 15 May 2009, 9:36:18 EDT
- Vaccine against HER2-positive breast cancer offers complete protection in labMon, 15 Sep 2008, 5:36:14 EDT
- Breast density associated with increased risk of cancer recurrenceMon, 9 Nov 2009, 5:15:06 EST